| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
The lipids of the Gram-negative marine bacterium Marinobacter hydrocarbonoclasticus, cultivated in synthetic seawater on a single carbon source, acetate or n-icosane, were isolated, purified and their structures determined. Three different pools of lipids were isolated according to the sequential procedure used: "unbound" lipids extractable by solvents, lipids released under basic conditions ("ester bound") and lipids released by acid hydrolysis ("amide bound"). Even-carbon-numbered, n-fatty acids were identified in the "unbound" lipids of both the acetate and n-icosane cultures. In addition to these compounds, n-icosane induced the formation of n-icosan-1-ol and n-icos-11-en-1-ol, and also of a series of ß-hydroxy acids ranging from C12 to C20. In the "ester bound" lipids of the two cultures, short and long chain fatty acids were identified together with the ß-hydroxy C12:0 acid. This hydroxy acid was, by far, the major compound identified in the "amide bound" lipids of the two cultures. Comparison of the analytical data for the two cultures, and the differences in composition thus observed for the "unbound" pool, suggest the following metabolic pathway for n-icosane: hydroxylation to the C20 primary alcohol, transformation into the C20 ß-hydroxy acid and subsequent degradation into lower homologues. In sharp contrast, lipids from the "ester bound" and "amide bound" pools were quite unaffected by the change of nutrient. Lipids from Escherichia coli were also examined in the same manner. The results are discussed in terms of geochemical implications, relative to the presence of "unbound" ß-hydroxy acids in particulate matter and sediments. |
|---|---|
| References | |
| Additional Infomation |
Icosan-1-ol is a long-chain primary fatty alcohol that is icosane in which one of the terminal methyl hydrogens is replaced by a hydroxy group. It has a role as a plant metabolite, a volatile oil component and a human metabolite. It is a long-chain primary fatty alcohol and an icosanol.
1-Eicosanol has been reported in Pyracantha angustifolia, Plumeria rubra, and other organisms with data available. |
| Molecular Formula |
C20H42O
|
|---|---|
| Molecular Weight |
298.55
|
| Exact Mass |
298.323
|
| CAS # |
629-96-9
|
| Related CAS # |
1-Eicosanol-d41; 349553-89-5
|
| PubChem CID |
12404
|
| Appearance |
White to off-white solid
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
309.0±0.0 °C at 760 mmHg
|
| Melting Point |
62-65 °C(lit.)
|
| Flash Point |
141.6±5.2 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.453
|
| LogP |
9.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
21
|
| Complexity |
167
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
BTFJIXJJCSYFAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H42O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21/h21H,2-20H2,1H3
|
| Chemical Name |
icosan-1-ol
|
| Synonyms |
Arachidyl alcohol; 1-Eicosanol; Icosyl Alcohol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 2 mg/mL (6.70 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3495 mL | 16.7476 mL | 33.4952 mL | |
| 5 mM | 0.6699 mL | 3.3495 mL | 6.6990 mL | |
| 10 mM | 0.3350 mL | 1.6748 mL | 3.3495 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06178367 | Completed | Drug: Vehicle Drug: High molecular weight hyaluronic acid |
Xerosis Cutis | Indonesia University | August 26, 2023 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
